56 results about "Acute renal shutdown" patented technology

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins.

The present invention relates generally to a method for the treatment of renal failure or renal hypertension and, more particularly, for improving the recovery from acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase.

The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).

Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.

The invention provides a biological reaction device which replaces human kidney, consisting of a biological reactor, a peristaltic pump, a cell culture liquid constant-flow device and a constant temperature box; the biological reactor consists of a plastic shell, a pouring liquid inlet, a pouring liquid outlet, a cell culture liquid inlet, a cell culture liquid outlet, a sulfone film nanometer supporting layer and a hollow fiber pipe; the hollow fiber pipe is arranged in a concentric round; the peristaltic pump is connected with the pouring liquid inlet and the pouring liquid outlet of the biological reactor; the constant-flow device is connected with the cell culture liquid inlet and outlet of the biological reactor; the biological reactor, the peristaltic pump and the constant-flow device are arranged inside the constant temperature box; the biological reaction device has reasonable design and simple and convenient preparation, can replace the kidney function of acute renal failure and multiple organ dysfunction syndrome patient in long-term or leads the similar patients to gradually recover the self-kidney tissue and other functions, thus improving the survival rate of the multiple organ dysfunction syndrome patient and prolonging the survival time of the multiple organ dysfunction syndrome patients.

The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.